Navigation Links
Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
Date:1/27/2009

CALGARY, Jan. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that patient enrolment has begun in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN(R) in patients with metastatic colorectal cancer prior to surgical resection of liver metastases. The principal investigator is Professor Alan Melcher of St. James's University Hospital.

"This study allows us to assess a resected tumour after REOLYSIN(R) treatment has been administered, giving us vital information about how effective REOLYSIN(R) delivery really is in patients," said Prof. Melcher. "REOLYSIN(R) will be given to patients before their planned operation, which is part of the patient's standard clinical care. In addition to possible benefit to patients, this data will tell us more about how REOLYSIN(R) kills cancer cells; helping to guide future research and development of the agent."

The trial (REO 013) is an open-label, non-randomized, single centre study of REOLYSIN(R) given intravenously to patients for five consecutive days in advance of their scheduled operations to remove colorectal cancer deposits metastatic to the liver. Patients will comprise two groups receiving REOLYSIN(R), either at an early (21 to 10 days) or late time point (less than 10 days) before surgical resection. After surgery, the tumour and surrounding liver tissue will be assessed for viral status and anti-tumour effects.

"We are pleased that our U.K. colleagues are sponsoring additional clinical research using REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of Oncolytics. "With the U.S. National Cancer Institute trials underway, three REOLYSIN(R) trials are now being sponsored by our collaborators."

The primary objectives of the trial are to assess the presence, replication and anti-cancer effects
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
2. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
3. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
4. Researchers at Axial Biotech Develop a DNA Test for Scoliosis
5. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
6. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
7. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
8. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
9. Pulmo BioTech Inc. Completes Bio-Distribution Studies
10. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
11. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Immune Pharmaceuticals, ... CEO, Dr. Daniel Teper , will present live ... August 6, 2015 TIME:   11:30AM EDT LINK:    ... live, interactive online event where investors are invited to ... the presentation hall as well as the association,s "virtual ...
(Date:8/3/2015)... (PK:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2016 ... The Company posted quarterly net revenue of $2.454 million ... $(0.02) per share. These results compare to net revenue ... thousand, or $(0.02) per share, in the year-ago quarter. ...
(Date:8/3/2015)... 3, 2015 Shire plc ... that it has acquired New York ... $300 million. With the acquisition, Shire acquires the ... 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), a ... infectious conjunctivitis, an ocular surface condition commonly referred ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6
... Nov. 11, 2010 Results of ... RE-LY® trial,(1) involving the newly approved oral anticoagulant ... at the American Heart Association,s Annual Scientific Sessions ... the prognostic value of two separate biomarkers (D-dimer ...
... Nov. 11, 2010 MedClean Technologies (OTC Bulletin Board: ... technology for the treatment and disposal of medical waste ... today announced it has signed an agreement with Gamma ... of a MedClean 4500 fixed-based sterilization system. ...
Cached Medicine Technology:New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions 2New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions 3New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions 4New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions 5New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions 6MedClean Technologies Signs Contract with Gamma HealthCare Inc./Danner Medical Waste for MedClean 4500 Fixed-Based System, Services, and Consumables 2MedClean Technologies Signs Contract with Gamma HealthCare Inc./Danner Medical Waste for MedClean 4500 Fixed-Based System, Services, and Consumables 3MedClean Technologies Signs Contract with Gamma HealthCare Inc./Danner Medical Waste for MedClean 4500 Fixed-Based System, Services, and Consumables 4
(Date:8/3/2015)... ... 2015 , ... The Workgroup for Electronic Data Interchange ( WEDI ), the ... healthcare information exchange, announced the release of its findings from its June 2015 ICD-10 ... WEDI shared survey results and recommendations , strongly encouraging the department ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... services to contract research organisations (CROs) for a slew of benefits, allowing them ... research and operations, boost quality with cost-effective utilisation of resources, get access to ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... the largest online retailer of nutritional supplements, has officially opened the polls ... 11 awards in the following categories:, ,     Brand of ...
(Date:8/3/2015)... ... ... The art of preparing and cooking food comes naturally to some. For ... Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is skilled ... Kitchen with the world. , Since Americans tend to be undereducated about Persian cuisine, ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2
... study it is observed by researchers that children who light ... to become smokers themselves. In addition, asking children to bring ... cigarette for the parent are all behaviors that encourage children ... University, feel that when a parent asks his child to ...
... better if specialists in critical care medicine manage them ... analysed the evidence on managing patients in intensive care ... better if they are cared for by a doctor ... ,Previous research has suggested that the involvement of ...
... study, researchers suggest that the presence of proteins linked ... men with high blood pressure. Although we know that ... //it's still the case that not everyone with hypertension ... believe that inflammation could be the key to understanding ...
... in their immune system that make them more vulnerable ... health, although the underlying// mechanisms are not clear. Now ... exposure to chronic stress has a specific effect on ... up - in response to infection - this is ...
... eat a lot of fruits and vegetables which increases by ... different factors influence the variety and content of people's daily ... of South Carolina, one of these is the convenience of ... in 200 US neighborhood areas. ,Six times more ...
... Contractures are very common in patients who undergo lower ... is important to prevent such complications. That patient ... bent position, which is incorrect.// The correct position is ... are taught to the patient for all the limbs ...
Cached Medicine News: